How much market share does tenofovir alafenamide (TAF) have?
Market-share figures for tenofovir alafenamide are not provided in the information available here. [No source data was included.]
Market share by region or country?
Common ways to break out “market share” include region (US, EU, China, Japan, etc.) and therapy area (HIV vs. hepatitis B). No regional or country market-share data is included in the provided material. [No source data was included.]
Market share versus tenofovir disoproxil fumarate (TDF)?
TAF is generally positioned as a newer alternative to TDF for chronic HIV and hepatitis B treatment, but specific competitive market-share numbers versus TDF are not present in the provided information. [No source data was included.]
Share inside HIV treatment portfolios vs hepatitis B portfolios
TAF is used across HIV and hepatitis B regimens, so “market share” can mean different things depending on whether you’re counting by:
- total branded prescriptions
- total patients on therapy
- revenue (sales) share
No breakdown is available from the provided information. [No source data was included.]
If you meant “TAF share of total antiretrovirals,” what counts as the denominator?
Market share can vary widely depending on the denominator (all antiretrovirals, all HBV drugs, nucleotide reverse transcriptase inhibitors only, etc.). The needed definitions and datasets are not included here. [No source data was included.]
What I need to calculate or report TAF market share accurately
If you share either (a) the dataset/source you want used or (b) the region/time period and what metric you mean (units, patients, or revenue), I can help you compute or structure the market-share answer:
- product names/brands to include under “TAF”
- geography (global or specific countries)
- timeframe (e.g., 2023, Q1 2024)
- metric (prescriptions, patient share, or sales)
Sources
No sources were provided with the question, so no citations could be added.